Theodore Meltzer, PhD - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

KeywordLocation
About Search
Theodore Meltzer, PhD


Theodore Meltzer, PhD
Principal,
Capitola Consulting Co.

Theodore H. Meltzer, PhD, is a private consultant. His services focus on pharmaceutical and other fine filtration requirements, and on ultrapure water operations for the pharmaceutical and semiconductor industries. His consultative assignments have dealt with such marketing and sales activities as product acceptance and market-sizing assessments. His experiences include serving as expert in litigations, particularly in patent matters involving filters compositions, specific applicational requirements, and prior art.

Previously he was employed by filter manufacturers in such capacities as vice-president of membrane production; director of R&D; and as acting director of marketing and sales.

Dr. Meltzer is a member of several technical societies.  He is an honorary member of PDA.  He heads the PDA Pharmaceutical Water Interest Group, and has close, if unofficial, ties with his opposite numbers on the USP Water Expert Committee.  He has regularly presented courses both in the US and abroad on ‘High-Purity Water Systems Design and Validation’  ‘and on ‘Pharmaceutical Filtration and Its Validation’ for PDA, and for the Center for Professional Advancement.  He directed the annual Ultrapure Water Conference for 10 years, and is utilized by the FDA for presentations on pharmaceutical filtration in its inspector training sessions. He is a reviewer for the PDA Journal of Pharmaceutical Science & Technology, and is on the review boards of Pharmaceutical Technology and American Pharmaceutical Review.

Meltzer lectures widely and has published roughly 100 papers.  He holds four patents and has authored or coauthored nine books, and has written several book chapters.

Trained as a polymer chemist, he holds a BS in chemistry from the College of the City of New York, an MA in preparative organic and biochemistry from the University of Wisconsin, and a PhD in physical organic from the University of Chicago. He performed postdoctoral work on the mechanical properties of polymers at Princeton University.  He was elected to the Sigma Xi, the national honorary scientific society, while at the University of Chicago.

ADVERTISEMENT

post a comment
Your email address will NOT be published.
appears with your comment
read our privacy policy
Note: does not support HTML
All comments submitted are subject to review, and may be delayed before posting. We reserve the right not to post comments.
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What factor do you think will be most significant in 2010 for determining the health of the market for contract manufacturing of active pharmaceutical ingredients?
The global economic recovery
The US economic recovery
Improved credit and financing flow to the small to emerging pharma/bio sector
Less restrictive inventory control by pharmaceutical companies
The level of competition from contract manufacturers in emerging markets
The global economic recovery
39%
The US economic recovery
14%
Improved credit and financing flow to the small to emerging pharma/bio sector
15%
Less restrictive inventory control by pharmaceutical companies
8%
The level of competition from contract manufacturers in emerging markets
24%
View Results
Eric LangerOutsourcing OutlookEric Langer A Bio View of Outsourcing
Patricia Van ArnumIngredients InsiderPatricia Van Arnum Advances in Custom Synthesis
Faiz kermaniSpotlightFaiz Kermani EU pricing dilemmas
Faiz kermaniStatistical Solutions Lynn Torbeck%RSD: Friend or Foe?
Keep an eye on that cargo
Pharma packs a punch
Another Boost for Vaccines
Rodney Dangerfield and R&D
Federal Spending Freeze Could Threaten Supply-Chain Security
FindPharma Custom Search

Click here